Domenico Mallardo

Statistics

Publications

Citations

3.2K

H-Index

Active since

2016

Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Sapienza University of Rome

Karolinska Institutet

Ospedale Policlinico San Martino

Domenico Mallardo is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in immunology, tumor microenvironment, and immunotherapy.

ORCID

Top concepts

MedicineImmunologyImmunotherapyTumor MicroenvironmentOncologyPathologyCancer TherapyHealthCell BiologyCancer Research

Publications per year

2016–2024

Publications

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Mariaelena Capone, Diana Giannarelli, Domenico Mallardo et al. · Journal for ImmunoTherapy of Cancer · 2018 · 499 citations · Full text

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Clélia Coutzac, Jean-Mehdi Jouniaux, Angélo Paci et al. · Nature Communications · 2020 · 441 citations · Full text

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 250 citations · Full text

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci et al. · Journal of Clinical Oncology · 2022 · 208 citations

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 146 citations · Full text

1–5 of 40